Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773929 · ClinicalTrials.gov registry record · Phase 1
Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00773929 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00773929, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.
Interventions
- DRUG TAK-593
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773929
The ClinicalTrials.gov registry entry for NCT00773929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-593 is the first listed.
NCT00773929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00773929 about?
NCT00773929 is a clinical study titled "Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer". The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.
What is the current status of trial NCT00773929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2009-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00773929?
The interventions under investigation include: TAK-593 (DRUG).
Who is sponsoring clinical trial NCT00773929?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.